Determinants of Myelosuppression in the Treatment of Non-small Cell Lung Cancer with Cisplatin-containing Chemotherapy
スポンサーリンク
概要
- 論文の詳細を見る
- 1996-07-31
著者
-
Fukuoka Masahiro
Osaka Phase I Study Group
-
Minakuchi Kazuo
大阪府立呼吸器・アレルギー医療センター 肺腫瘍内科
-
Kudoh S
Osaka Phase I Study Group
-
Kubota Kaoru
Department Of Internal Medicine National Kinki Central Hospital
-
Masuda Noriyuki
The Second Department Of Internal Medicine Osaka Prefectural Habikino Hospital
-
MATSUI Kaoru
2nd Department of Internal Medicine, Osaka Prefectural Habikino Hospital
-
MASUDA Noriyuki
2nd Department of Internal Medicine, Osaka Prefectural Habikino Hospital
-
UCHIDA Yasuo
Scientific Affairs Department, Pharmaceuticals Group. Nippon Kayaku Co., Ltd.,
-
FUKUOKA Masahiro
2nd Department of Internal Medicine, Osaka Prefectural Habikino Hospital
-
NEGORO Shunichi
2nd Department of Internal Medicine, Osaka Prefectural Habikino Hospital
-
YANA Takashi
2nd Department of Internal Medicine, Osaka Prefectural Habikino Hospital
-
KUSUNOKI Yoko
2nd Department of Internal Medicine, Osaka Prefectural Habikino Hospital
-
KUDOH Shinzoh
2nd Department of Internal Medicine, Osaka Prefectural Habikino Hospital
-
KAWASE Ichiro
2nd Department of Internal Medicine, Osaka Prefectural Habikino Hospital
-
KAWAHARA Masaaki
Department of Internal Medicine, National Kinki Central Hospital
-
OGAWARA Mitsumasa
Department of Internal Medicine, National Kinki Central Hospital
-
KODAMA Nagahisa
Department of Internal Medicine, National Kinki Central Hospital
-
FURUSE Kiyoyuki
Department of Internal Medicine, National Kinki Central Hospital
-
Negoro Shunichi
Osaka Phase I Study Group
-
Ogawara Mitsumasa
Department Of Internal Medicine National Kinki Central Hospital
-
FURUSE Kiyoyuki
Osaka Central Hospital
-
YANA Takashi
the Second Department of Internal Medicine, Osaka Prefectural Habikino Hospital
-
Kobayashi Masashi
Tzt-1027 Cooperative Study Group
-
Kawase Ichiro
2nd Department Of Internal Medicine Osaka Prefectural Habikino Hospital
-
Matsui Kaoru
Department Of Thoracic Malignancy Osaka Prefectural Medical Center For Respiratory And Allergic Dise
-
Yana Takashi
The Second Department Of Internal Medicine Osaka Prefectural Habikino Hospital
-
Uchida Yasuo
Scientific Affairs Department Pharmaceuticals Group. Nippon Kayaku Co. Ltd.
-
Kusunoki Yoko
2nd Department Of Internal Medicine Osaka Prefectural Habikino Hospital
-
Minakuchi Kazuo
Department Of Thoracic Malignancy Osaka Prefectural Medical Center For Respiratory And Allergic Dise
-
Kubota Kaoru
Department Of Cardiovascular Dynamics Research Institute National Cardiovascular Center
-
Furuse K
Osaka Central Hospital
-
Furuse Kiyoyuki
Department Of Internal Medicine National Kinki Central Hospital For Chest Diseases
-
Kodama Nagahisa
Department Of Internal Medicine National Kinki Central Hospital
-
Kawahara Masaaki
Department Of Applied Chemistry Faculty Of Engineering Saitama Universtiy
関連論文
- Determinants of Myelosuppression in the Treatment of Non-small Cell Lung Cancer with Cisplatin-containing Chemotherapy
- Phase I and Pharmacokinetics Trial of BNP7787 in Patients Receiving Cisplatin and Paclitaxel
- Early phase ll study of S-1, a new oral fluoropyrimidine, for advanced non-small-cell lung cancel
- Enhancement of Tumor Radio-response by Irinotecan in Human Lung Tumor Xenografts
- Relationship between the Pharmacokinetics of Irinotecan and Diarrhea during Combination Chemotherapy with Cisplatin
- E-22 Establishment of Tumor Cell Lines as An Independent Prognostic Factor in Small Cell Lung Cancer (SCLC)
- 65 Seven Small Cell Lung Cancer (SCLC) Cell Lines established from Bronchofiberscope Biopsies
- Impact of main bronchial lymph node involvement in pathological T1-2N1M0 non-small-cell lung cancer : multi-institutional survey by the Japan National Hospital Study Group for Lung Cancer
- Radiation Pneumonitis following Multi-Field Radiation Therapy
- Non-small cell lung cancer : radiation therapy for locoregional recurrence after complete resection
- Proteomics-based identification of α-enolase as a tumor antigen in non-small lung cancer
- Preliminary experience with a modified premedication protocol that included intravenous diphenhydramine and calcium bromide for the prophylaxis of paclitaxel-related hypersensitivity reactions
- Phase I study of TZT-1027, a novel synthetic dolastatin 10 derivative and inhibitor of tubulin polymerization, given weekly to advanced solid tumor patients for 3 weeks
- Phase I studies of nogitecan hydrochloride for Japanese
- Carboplatin Calculated with Chatelut's Formula Plus Etoposide for Elderly Patients with Small-Cell Lung Cancer
- Phase I study of weekly cisplatin, vinorelbine, and concurrent thoracic radiation therapy in patients with locally advanced non-small-cell lung cancer
- A Single Institutional Subset Analysis of the WJLCG Study Comparing Concurrent and Sequential Chemoradiotherapy for Stage III Non-small-cell Lung Cancer
- On Public Health Activities in Ccylon and Results of Some Medical Surveys for Ceylonese
- Pleural sarcomatoid malignant mesothelioma consisting of histiocytoid cells
- Pleural MALT lymphoma diagnosed on thoracoscopic resection under local anesthesia using an insulation-tipped diathermic knife
- Relation between Peak Expiratory Flow and Quality of Life in Asthmatic Patients
- Correlation of Peak Expiratory Flow Rate with Exercise Tolerance in Stable Asthmatic Patients
- AUC finding study of daily carboplatin administration combined with concurrent thoracic radiotherapy for elderly non-small cell lung cancer patients
- Double-blind randomized control trial of the effect of recombinant human erythropoietin on chemotherapy-induced anemia in patients with non-small cell lung cancer
- Multicenter, phase II, placebo-controlled, double-blind, randomized study of aprepitant in Japanese patients receiving high-dose cisplatin
- Promotion of the Oxidation of Nitric Oxide and Hydrocarbon by the Thermal Decomposition of Peroxyacetyl Nitrate (PAN) at Night
- Response to Paulo et al. : Japanese patients equally likely to benefit from aprepitant for chemotherapy-induced nausea and vomiting prevention
- Arginase activity in peripheral erythrocytes in developing individuals.